Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group.
Authors
Ng, AYahalom, J
Goda, J
Constine, L
Pinnix, C
Kelsey, C
Hoppe, B
Oguchi, M
Suh, C
Wirth, A
Qi, S
Davies, A
Moskowitz, C
Laskar, S
Li, Y
Mauch, P
Specht, L
Illidge, Timothy M
Affiliation
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MassachusettsIssue Date
2018-03-01
Metadata
Show full item recordAbstract
Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.Citation
Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. 2018, 100(3):652-669 Int J Radiat Oncol Biol PhysJournal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2017.12.005PubMed ID
29413279Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
1879-355Xae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2017.12.005
Scopus Count
Collections
Related articles
- Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
- Authors: Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J
- Issue date: 2015 May 1
- Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
- Authors: Gisselbrecht C
- Issue date: 2008 Dec
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
- Authors: Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG
- Issue date: 2015
- A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
- Authors: Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H
- Issue date: 2017 Sep
- Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
- Authors: Biswas T, Dhakal S, Chen R, Hyrien O, Bernstein S, Friedberg JW, Fisher RI, Liesveld J, Phillips G, Constine LS
- Issue date: 2010 May 1